Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Large Decline in Short Interest

Posted by Geri Gentry on Sep 1st, 2026

Enlivex Therapeutics Ltd. (NASDAQ:ENLV – Get Free Report) saw a large decline in short interest in the month of August. As of August 14th, there was short interest totaling 104,202 shares, a decline of 41.3% from the July 30th total of 177,544 shares. Currently, 0.7% of the shares of the company are short sold. Based on an average daily trading volume, of 316,969 shares, the days-to-cover ratio is presently 0.3 days.

Enlivex Therapeutics Stock Performance

ENLV stock remained flat at $1.28 on Tuesday. The company had a trading volume of 343,329 shares, compared to its average volume of 102,825. The company has a fifty day moving average of $4.25 and a two-hundred day moving average of $10.29. The company has a market cap of $22.39 million, a price-to-earnings ratio of -0.16 and a beta of 1.60. Enlivex Therapeutics has a 52-week low of $1.15 and a 52-week high of $27.15.

Institutional Trading of Enlivex Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ENLV. Virtu Financial LLC acquired a new stake in shares of Enlivex Therapeutics during the 4th quarter valued at approximately $33,000. Susquehanna International Group LLP acquired a new position in Enlivex Therapeutics during the third quarter worth $57,000. Invesco Ltd. acquired a new position in Enlivex Therapeutics during the fourth quarter worth $43,000. XTX Topco Ltd boosted its position in Enlivex Therapeutics by 44.8% during the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after purchasing an additional 19,132 shares in the last quarter. Finally, Jane Street Group LLC boosted its position in Enlivex Therapeutics by 244.1% during the fourth quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock worth $52,000 after purchasing an additional 52,553 shares in the last quarter. Hedge funds and other institutional investors own 1.02% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. Zacks Research upgraded shares of Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. Finally, Wall Street Zen raised shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $247.50.

Get Our Latest Report on Enlivex Therapeutics

Enlivex Therapeutics Company Profile

(Get Free Report)

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.